362 related articles for article (PubMed ID: 22213157)
1. Do persons with diabetes benefit from combination statin and fibrate therapy?
Rosenblit PD
Curr Cardiol Rep; 2012 Feb; 14(1):112-24. PubMed ID: 22213157
[TBL] [Abstract][Full Text] [Related]
2. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
3. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM
Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
[TBL] [Abstract][Full Text] [Related]
5. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
6. Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?
Agouridis AP; Rizos CV; Elisaf MS; Filippatos TD
Rev Diabet Stud; 2013; 10(2-3):171-90. PubMed ID: 24380091
[TBL] [Abstract][Full Text] [Related]
7. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus.
Reyes-Soffer G; Rondon-Clavo C; Ginsberg HN
Expert Opin Pharmacother; 2011 Jun; 12(9):1429-38. PubMed ID: 21426238
[TBL] [Abstract][Full Text] [Related]
9. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe?
Milionis H
Expert Opin Drug Saf; 2014 Mar; 13(3):267-9. PubMed ID: 24512564
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus.
Wanner C; Krane V
Kidney Blood Press Res; 2011; 34(4):209-17. PubMed ID: 21691123
[TBL] [Abstract][Full Text] [Related]
11. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
Moutzouri E; Kei A; Elisaf MS; Milionis HJ
Vasc Health Risk Manag; 2010 Aug; 6():525-39. PubMed ID: 20730069
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.
Lee M; Saver JL; Towfighi A; Chow J; Ovbiagele B
Atherosclerosis; 2011 Aug; 217(2):492-8. PubMed ID: 21592479
[TBL] [Abstract][Full Text] [Related]
13. Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
Kayıkçıoğlu M; Shahbazova S; İbrahimov F; Can LH
Turk Kardiyol Dern Ars; 2020 Jun; 48(4):359-367. PubMed ID: 32519982
[TBL] [Abstract][Full Text] [Related]
14. Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
Brinton EA
Curr Atheroscler Rep; 2008 Feb; 10(1):25-32. PubMed ID: 18366982
[TBL] [Abstract][Full Text] [Related]
15. How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.
Steiner G
Cardiovasc Drugs Ther; 2009 Oct; 23(5):403-8. PubMed ID: 19757004
[TBL] [Abstract][Full Text] [Related]
16. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
17. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.
; Buse JB; Bigger JT; Byington RP; Cooper LS; Cushman WC; Friedewald WT; Genuth S; Gerstein HC; Ginsberg HN; Goff DC; Grimm RH; Margolis KL; Probstfield JL; Simons-Morton DG; Sullivan MD
Am J Cardiol; 2007 Jun; 99(12A):21i-33i. PubMed ID: 17599422
[TBL] [Abstract][Full Text] [Related]
18. Hyperlipidaemia and cardiovascular disease: do fibrates have a role?
Saha SA; Arora RR
Curr Opin Lipidol; 2011 Aug; 22(4):270-6. PubMed ID: 21519250
[TBL] [Abstract][Full Text] [Related]
19. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study.
Zhu L; Hayen A; Bell KJL
Cardiovasc Diabetol; 2020 Mar; 19(1):28. PubMed ID: 32138746
[TBL] [Abstract][Full Text] [Related]
20. Fibrate therapy in the management of diabetic dyslipidemia: there is no ACCORD to be found.
Toth PP
Curr Atheroscler Rep; 2010 Sep; 12(5):331-5. PubMed ID: 20623343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
